Clinical effect of a sustained-release theophylline formulation in moderate or severe asthmatic patients with intercrisis

Linares Borges, A.; Rodríguez Muñiz, J.M.; Alemán Aguilar, H.; Yamir Betancourt, B.; Jiménez Hernández, L.; Chala Tandrón, J.M.; Martín García, L.M.; de la Vega Elías, L.

Revista Alergia Mexico 47(2): 65-69

2000


ISSN/ISBN: 0002-5151
PMID: 10872308
Document Number: 6342
The clinical effect of the formulation of theophylline of sustained action was evaluated (Aristegui 300 mg, capsules) to the dose of 9 weight/day mg/kg (every 12 hours) in the consultation of bronchial asthma of Hospital Docente Provincial Clínico Quirúrgico de Santa Clara, in the understood period of February to September of 1997. The time of treatment was of one month and they were carried out five consultations. The sample was constituted by 30 asthmatic, moderate or severe patients. The variables were analyzed: attendance to guard's body, salbutamol use in spray and they were carried out objective mensurations from the lung function to all the patients in the different consultations. With the use of the formulation they diminished the flow expiratory pick significantly, the expiratory volume forced in one second and the flow half expiratory maximum and low incidence of adverse effects existed.

Document emailed within 1 workday
Secure & encrypted payments

Clinical effect of a sustained-release theophylline formulation in moderate or severe asthmatic patients with intercrisis